Updates

  1. 137 new fund letters and reports, each with its own page: Kayne Anderson Rudnick (48 market briefings, KayneCast episodes and TV commentaries), Shelton Capital Management (48 shareholder reports and a commentary), Lakehouse Capital (10 Small Companies Fund letters), Smead (5 newsletters), RIT Capital Partners (5 monthly commentaries), Kovitz, Legal & General, Generation, Hosking, Marram, Munro, Oldfield and others.
  2. 200 new fund letters and reports, each with its own page: Spheria (41 monthly reports), Peapack Private (41 weekly recaps and planning newsletters), Fort Washington (23), Polen Capital (15), Aristotle Pacific (14), Riverwater (13), Chou (10), Apollo Asia Fund (8, back to 1998), Personal Asset Trust, Rockwood Strategic, J Capital Research, I/O Fund, Penn Davis McFarland, Pomona and others.
  3. Investor pages have one Investments tab with shares, changes, % owned, class, market cap and Market cap and Status filters, a Funds tab listing each fund the firm runs, and assets under management from Form ADV. The Investors table shows AUM and current investments, and its search finds investors by what they hold.
  4. Filters, search and sort stay as you left them when you come back to a section. Person cards look like book cards. Company pages name their Investors tab Ownership. Kind and Sector filters use four kinds and GICS sectors with industries. Dead links left the Links tabs.
  5. 190 more investors from fiscal.ai's list, with their sites, letters, partners and 13F holdings; 556 more partner descriptions. Experts now lists only people.
  6. Fund letters lists 144 new documents from 23 firms, each with its own page: a summary, key insights and quotes. Among them: 37 BlackRock articles, 21 Value Partners monthly notes, eight Baron Capital letters, six Stone Sentinel letters to partners, seven Value Line portfolio manager Q&As, BNY's 2026 earnings releases and Starboard Value's 2026 conference presentations.
  7. 584 more investors, with their websites, 6,776 letters from their own sites, 1,385 partners with pages and the 13F holdings of 213 firms. New letters arrive daily from 290 more archives.
  8. Media and Companies filter by GICS sector and industry group, taken from the companies an episode or page names. 1,860 more company pages show a logo, the SEC's list included.
  9. The home page counts what the platform holds and lists features such as the document reader, the player and saved marks. Settings sits at the foot of the rail. Book cards are a quarter wider, so rows hold fewer. Companies drops the Named in filter, and the Role list in your account runs A to Z.
  10. Investor pages of 13 firms show their newsroom's latest posts. New 13F filings are read as the SEC publishes them.
  11. Investor pages have an Investments tab: 13,975 holdings for 105 investors, from their 13F filings with the SEC and their own portfolio pages, with status and sector. 7,338 more companies have a page of their own.
  12. A podcast or YouTube episode keeps playing while you move around the site, in a bar with skip, speed and volume. Media tables show each episode's length and description.
  13. Press releases come from each company's own newsroom (167 companies); SEC filings sit on the Filings tab. Tickers name their exchange, and a company's Experts tab includes guests whose episode description names it.
  14. Letter types now include Market commentary, Fact sheet, Interim report, Annual report, Proxy circular and Governance document. The reader opens over the whole window.
  15. Partners of investment firms have 2,836 appearances and 580 pieces of writing on their pages; Derek Sivers's page lists every book he rates, with his rating.
  16. Fund letters lists three Akre Focus shareholder reports: the ETF's annual report for the year to July 2026, its semi-annual report to January 2026 and the fund's semi-annual report to January 2025, each with its own page: a summary, key insights and quotes.
  17. 837 partners of 73 investment firms now have their own pages, with title, description, photograph and social accounts; Andreessen Horowitz partners' pages also list their writing on a16z.com.
  18. Company pages have a Press releases tab: 8,229 releases for 203 companies, from SEC filings and company newsrooms. Companies filter by For-profit or Non-profit. Own media is a table with filters. Media filters by sector and industry. Publication pages link their publisher in the description.
  19. The Unilever page's Letters tab shows what each fund letter says about Unilever, word for word with its page, and whether the letter is bullish, bearish, mixed or neutral. Filter by sentiment, and see 10 letters at a time.
  20. 492 more fund letters and 3,183 more articles show the day they were published, read from each letter's first page or each article's own page.
  21. The PDF reader has a search box: type words to see every match in the document and step through them. About 540 letters that were web pages, among them Oakmark's commentaries, Bill Miller's letters and Howard Marks's memos, now open in the reader.
  22. Person pages: recommendations open with tier 1 books; one button per organisation; transcripts sit on their episodes; the books on 129 reading lists joined the Recommends tabs.
  23. Companies lists every company with a ticker on the SEC's list, with a Source filter. A quote on a company page opens the letter at that page with the words marked. A company's Media tab lists only episodes that name it, and a new Own media tab lists its podcasts, publications and YouTube channel. Show pages link their publisher. A page opened from a table no longer shows that table's filters beside it.
  24. Company, investor and person pages show more of their social accounts: Facebook, TikTok, Bluesky, Medium, GitHub, Discord and podcast shows. Investor pages list every partner the firm's own team page names: 965 people across 73 investors, 98 for Andreessen Horowitz.
  25. About 170 more letters and papers open in the reader: Mohnish Pabrai's letters and transcripts from his site's new folder, and free copies of papers by Asness, Harvey, Altman, Lo and others from their own or their schools' sites.
  26. Every company a fund letter names has a page, with the letters and quotes that name it: 47 new pages, among them Atom Computing, Hugging Face, Rolls-Royce Holdings and Westinghouse Electric. Company pages have a Quotes tab.
  27. A person's Writing tab has a Type column and filter (Article, Essay, Transcript, Speech, Foreword, Interview and the rest), and Publication names only the publication that published each piece.
  28. Fund letters opens on the newest published letter, and a letter or paper found by search opens its own page here instead of the publisher's site.
  29. A letter or paper with a copy on the site opens its PDF over its page, with a button to open it in a new tab. Select text to highlight or underline it; signed-in readers keep their marks in their account. Each quote opens the PDF at its page with its words marked, and a Source link leads to the publisher's original.
  30. Fund letters lists 61 more documents, each with its own page: Fairfax's 2025 and 2026 interim reports, proxy circulars and 2025 annual report (with their French editions), 26 Charlie Munger meeting transcripts, talks and essays, Third Point's 2026 monthly reports and Malibu Life's interim results, and a Seth Klarman interview. Papers adds Richard Thaler's two 2020 editorials on nudges.
  31. Fund letters lists Lux Capital's letters for Q2 and Q3 2026, by Josh Wolfe, each with its own page: a summary, key insights and quotes.
  32. Fund letters lists Brookfield's letter to shareholders for Q3 2026, by Bruce Flatt, with its own page: a summary, key insights and quotes.
  33. Fund letters lists Howard Marks's memo of 11 November 2026, A Layman Thinks About AI, with its own page: a summary, key insights and quotes.
  34. Fund letters lists 118 more letters, each with its own page: 44 weekly commentaries by Jeremy Siegel from 2026, 31 issues of Van Tharp's newsletter from 2018, 23 Pabrai Investment Funds letters from 2021 to Q3 2026, 13 Efficient Frontier essays by William Bernstein, Oakmark's three 3Q 2026 commentaries, two Lindsell Train reports, a John Hussman comment and Third Point's Q3 2026 letter.
  35. 2,027 more books carry a one-line description in the Books table and on their pages; 7,067 of 7,715 have one, every tier 1, 2 and 3 book among them.
  36. Fund letters lists 187 more letters from 19 firms, among them Permanent Equity, Social Capital, Lux Capital, Square Peg, Bestinver, Cobas, Sequoia Fund, Marketfield and EquityCompass; each shows on its investor's page and has a page of its own.
  37. 2,928 more books carry a one-line description in the Books table and on their pages, so every tier 1, 2 and 3 book has one; 5,040 in all.
  38. Every publication on Newsletters has its own page: its writing, its writers, its staff and who recommends it. Investor pages have a Management tab; a company's Experts tab now leaves out its own people, who list under Management. Tabs on a phone move sideways only.
  39. Every fund letter and research paper has its own page: the thesis, the PDF, the companies and books it names, and for 176 letters and 24 papers so far a summary, key insights and quotes with their page.
  40. 99 books that no page listed now sit under their topics in Books, among them Caste, American Prometheus and Pale Blue Dot.
  41. Newsletters lists every newspaper, magazine, investment newsletter, journal and blog the reference holds, 442 in all, with the people who write there. The search box keeps your last 20 searches. You can create an account.
  42. 283 books that fund managers recommend in their letters are on the shelf, each with the letter's own words and page; investor pages have a Recommends tab.
  43. Person, company, investor and show pages link their own accounts on X, Threads, Instagram, LinkedIn, YouTube and Substack: 275 people, 552 companies and organisations, 88 investors and 478 shows.
  44. 716 more book recommendations name their source: the person's own reading list, letter, blog post, speech or interview, or an article that reports it. 232 of them quote the person's own words about the book, on the book card and on the book's page.
  45. Every US-listed company has a page with its SEC filings. Company pages list their experts and their management, past and present. Fund managers sit under Investors. Each show has a page of its episodes, and an episode page names its guests and hosts. Biographies lists groups, then people. Breadcrumbs show where a page sits.
  46. Media lists every podcast episode, video, interview and talk, over 10,000, by person, company, publisher and event; each filter searches its own choices. Books opens on its table, then Browse, then Authors and Recommenders. A filter's count no longer covers its arrow.
  47. A book that no company, country or subject page lists shows its topics under Where it sits in the reference. On a phone, a page's tabs scroll sideways only. Descriptions read the same on every page. See them in the Experts tab lists every expert the page names.
  48. Every podcast episode, video and interview has its own page with a video or audio player and a link to the source. Investor pages show each company's sector and market cap; firms such as Berkshire Hathaway have one page that holds their letters and their company tabs. Letters tabs filter by company and search the theses. Companies filter by Public, Private and Defunct and link each company's website.
  49. Every tab, view and search has its own address, such as /books/table/asset or /letters/companies, so Back works and a link opens the same place. Page addresses no longer end in .html. Fund letters, Investors, Companies and Papers load about a fifth of the data they did.
  50. Fund letters has a Companies tab: every company the letters name, with its market cap, sector, country, and how many letters and investors name it. Investor pages link each investor's website. Lists in table cells end with “… and N more” at every width.
  51. 1,120 more book summaries; descriptions for 373 papers; pages for 137 more companies, each with the fund letters that discuss it; 215 official photographs; search has its own page.
  52. 411 more books have a summary; person pages list 930 more of the books they wrote; 147 people show their official photograph.
  53. Every investor has a page with its letters and the companies they discuss; company pages list the investors whose letters name them.
  54. A Companies section at the top of the rail lists every company the books, experts and fund letters name.
  55. Person pages list letters, writing, profiles and links as sortable tables with filters, and show each person's companies as links; Fund letters show each letter's description in its own column.
  56. Experts show a checked job title and a short description of each person; 30 more people have photographs.
  57. Every company, fund, university and publication the experts work for has a page listing the people there.
  58. Fund letters show each letter's thesis and filter by it; 225 person pages list the essays, columns and newsletter issues the person wrote.
  59. Person pages list every essay and newsletter issue a person wrote, and their own books as a table in List view.
  60. Recommends shows the five largest kinds of book and the rest under More; browse pictures load sooner.
  61. Podcasts and talks link the original episode, filter by Audio and video or Press, and list each publisher once.
  62. Pages are wider, Recommends has List and Grid, and a filter clicked again turns off.
  63. Book cards sit in a ruled grid with Open Library and Goodreads links and each book's one-line note.
  64. Funds is now Investors; each investor's styles are buttons that filter the table.
  65. Podcasts and talks on a person's page filter by year and publisher and show as a list or a grid of pictures.
  66. Quotes show only people's own words: 472 summaries written by list sites are gone.
  67. Country pages open from Browse again, and every link on the shelf lands on a page.
  68. Subject and person pages show their sections as tabs, and each book appears once on a person's page.
  69. Book cards show the quote, who said it and the source; grids show five cards to a row.
  70. On a phone, a menu holds the sections, search, Updates, Feedback and dark mode.
  71. Feedback takes a screenshot of the page with no browser prompt, opens a screenshot full size when you click it, and clears itself once sent.
  72. Book cards are centred, search names the topic each book sits in, and any text cut short shows whole on hover.
  73. Search groups its results by kind: people, companies, geographies, subjects, topics, books, funds, fund letters and papers.
  74. The Books table lists who recommended each book by name, and the browser tab names the section you are in.
  75. Feedback can take a screenshot of the page, or one you paste or choose, and opens in the corner beside Updates.
  76. Each rail button reopens its section where you left it, and Browse, Table and People show on every book and subject page.
  77. Filters grey out choices that hold nothing instead of hiding them, and Books › People filters by authors or recommenders.
  78. Feedback takes a subject line and up to three screenshots.
  79. Biographies are grouped by the person they are about: 41 new pages, from Abraham Lincoln to Lee Kuan Yew.
  80. Sport splits into 23 sports, and Religion into one topic per faith.
  81. Book lists show as cards: the cover, one recommendation quote and every recommender by name.
  82. Seventeen subjects that had two or three pages under different names now have one page each.
  83. Every page lists its Experts as authors and recommenders, with a link to them on the Experts tab.
  84. Economics, Financial history, Financial panics and Accounting are subjects of their own, with one page per financial crisis.
  85. Book, person and subject pages open inside the app, so the tabs stay in view.
  86. 996 more book covers, and photographs or logos for 227 more people and companies.
  87. Books › Browse shows every subject as cards, and the rail holds Fund letters, Papers, Experts, Books and Funds.
  88. Every topic over 150 books splits into narrower topics, each with a page of its own.

Send feedback

What is it?
Screenshots, up to 3 (optional)
or paste one with Ctrl+V

We use your email only to reply to you.

RTW Investments

Asset Manager

We invest in biotech and medtech innovation across the full lifecycle from company creation to venture capital, alternative financing, and public companies.

AUM: $14.1B · Form ADV, 30 Mar 2026

i
Protagonist Therapeutics, IncNasdaq: PTGXCurrentPharmaceutical PreparationsCOM5,061,17500.0%7.75%$713M+$93M7.19%$8.1BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
ARGENX SENasdaq: ARGXCurrentBiological Products, (No Diagnostic Substances)SPONSORED ADR711,584+2,138+0.3%$682M+$24M6.88%$59.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
CG Oncology, Inc.Nasdaq: CGONCurrentBiological Products, (No Diagnostic Substances)COM8,514,59000.0%9.53%$604M-$1M6.08%$7.3BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
iRhythm Holdings, Inc.Nasdaq: IRTCCurrentSurgical & Medical Instruments & ApparatusCOM3,118,913+936,282+42.9%9.28%$354M+$95M3.57%$3.2BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
INSMED IncNasdaq: INSMCurrentPharmaceutical PreparationsCOM PAR $.013,096,545-1,746,335-36.1%1.41%$353M-$163M3.56%$31.7BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Tango Therapeutics, Inc.Nasdaq: TNGXCurrentPharmaceutical PreparationsCOM14,048,477+147,857+1.1%8.29%$351M-$84M3.53%$3.8BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Erasca, Inc.Nasdaq: ERASCurrentPharmaceutical PreparationsCOM22,446,754+4,500,000+25.1%6.40%$329M+$0.3M3.32%$5.0BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Spyre Therapeutics, Inc.Nasdaq: SYRECurrentPharmaceutical PreparationsCOM NEW3,691,791-560,205-13.2%3.89%$329M-$49M3.31%$9.3BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
RadNet, Inc.Nasdaq: RDNTCurrentServices-Medical LaboratoriesCOM4,630,697-216,261-4.5%5.88%$319M+$20M3.22%$5.5BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Tarsus PharmaceuticalsNasdaq: TARSCurrentBiological Products, (No Diagnostic Substances)COM3,484,066+127,007+3.8%7.07%$274M+$63M2.76%$3.8BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Zai Lab LtdNasdaq: ZLABCurrentPharmaceutical PreparationsADR10,350,973+3,776,941+57.5%$273M+$148M2.75%$2.7BQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
REPLIGEN CORPNasdaq: RGENCurrentBiological Products, (No Diagnostic Substances)COM1,385,398+144,761+11.7%2.17%$266M+$97M2.68%$10.9BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Guardant Health, Inc.Nasdaq: GHCurrentServices-Medical LaboratoriesCOM1,481,03300.0%1.09%$264M+$42M2.66%$19.7BQ3 202616 Nov 2026Q2 2025Q3 202613F, Q3 2026
Celcuity Inc.Nasdaq: CELCCurrentServices-Medical LaboratoriesCOM3,304,90300.0%6.73%$263M-$83M2.65%$2.8BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Oruka Therapeutics, Inc.Nasdaq: ORKACurrentPharmaceutical PreparationsCOM3,139,03000.0%4.63%$261M-$37M2.64%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Natera, Inc.Nasdaq: NTRACurrentServices-Medical LaboratoriesCOM600,000-400,000-40.0%0.41%$248M-$23M2.50%$42.0BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
CYTOKINETICS INCNasdaq: CYTKCurrentPharmaceutical PreparationsCOM NEW2,862,00300.0%2.05%$189M-$55M1.90%$7.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
UroGen Pharma Ltd.Nasdaq: URGNCurrentPharmaceutical PreparationsCOM4,543,89500.0%9.26%$185M+$17M1.86%$1.6BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Establishment Labs Hldgs IncCurrentCOM2,665,695+10,000+0.4%$171M-$57M1.72%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Xencor IncNasdaq: XNCRCurrentPharmaceutical PreparationsCOM6,827,461+50,000+0.7%9.10%$170M+$61M1.72%$2.6BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Madrigal PharmaceuticalsNasdaq: MDGLCurrentPharmaceutical PreparationsCOM312,817-1,680,870-84.3%1.35%$158M-$913M1.59%$9.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Immunocore Holdings plcNasdaq: IMCRCurrentBiological Products, (No Diagnostic Substances)ADS4,869,79800.0%9.42%$148M-$7M1.49%$1.4BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Stoke Therapeutics, Inc.Nasdaq: STOKCurrentPharmaceutical PreparationsCOM5,623,52500.0%8.60%$146M-$38M1.47%$1.8BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
ACADIA PHARMACEUTICALS INCNasdaq: ACADCurrentPharmaceutical PreparationsCOM7,144,52400.0%4.13%$144M-$37M1.45%$3.0BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Kodiak Sciences Inc.Nasdaq: KODCurrentBiological Products, (No Diagnostic Substances)COM1,487,93400.0%2.28%$141M+$83M1.42%$6.4BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
GH Research PLCNasdaq: GHRSCurrentPharmaceutical PreparationsORDINARY SHARES5,933,81500.0%$139M-$20M1.40%$1.3BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
COMPASS Pathways plcNasdaq: CMPSCurrentPharmaceutical PreparationsSPONSORED ADS10,948,591+247,617+2.3%7.73%$136M-$15M1.37%$1.2BQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
NEUROCRINE BIOSCIENCES INCNasdaq: NBIXCurrentBiological Products, (No Diagnostic Substances)COM942,684-325,241-25.7%0.93%$134M-$80M1.35%$15.8BQ3 202616 Nov 2026Q2 2025Q3 202613F, Q3 2026
Ultragenyx Pharmaceutical Inc.Nasdaq: RARECurrentPharmaceutical PreparationsCOM8,529,394+732,499+9.4%8.37%$128M-$132M1.29%$1.8BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Kailera Therapeutics, Inc.Nasdaq: KLRACurrentPharmaceutical PreparationsCOMMON STOCK10,776,82000.0%8.30%$123M-$114M1.24%$1.5BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
BELITE BIO, INCNasdaq: BLTECurrentPharmaceutical PreparationsSPONSORED ADS715,33200.0%$121M+$11M1.22%$6.1BQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Immatics N.V.Nasdaq: IMTXCurrentBiological Products, (No Diagnostic Substances)SHS13,521,551+575,375+4.4%$119M-$12M1.20%$906MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Replimune Group, Inc.Nasdaq: REPLCurrentBiological Products, (No Diagnostic Substances)COM8,491,525+1,079,944+14.6%8.96%$112M+$30M1.13%$1.8BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Immunovant, Inc.Nasdaq: IMVTCurrentBiological Products, (No Diagnostic Substances)COM3,177,84900.0%1.54%$107M-$15M1.08%$6.7BQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
PTC THERAPEUTICS, INC.Nasdaq: PTCTCurrentPharmaceutical PreparationsCOM1,615,819-6,130,596-79.1%1.93%$105M-$527M1.06%$4.9BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Viridian Therapeutics, Inc.\DENasdaq: VRDNCurrentPharmaceutical PreparationsCOM4,910,126+4,910,126New4.32%$101M+$101M1.02%$3.6BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
CASTLE BIOSCIENCES INCNasdaq: CSTLCurrentServices-Medical LaboratoriesCOM2,778,33500.0%9.02%$99M+$32M0.99%$1.0BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Uniqure NVCurrentSHS3,941,57200.0%$95M-$86M0.96%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Cogent BiosciencesNasdaq: COGTCurrentPharmaceutical PreparationsCOM2,309,02100.0%1.33%$74M-$15M0.75%$4.8BQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Structure Therapeutics Inc.Nasdaq: GPCRCurrentPharmaceutical PreparationsSPONSORED ADS2,282,138+674,631+42.0%1.06%$71M-$15M0.72%$1.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Axogen, Inc.Nasdaq: AXGNCurrentElectromedical & Electrotherapeutic ApparatusCOM1,659,376+647,800+64.0%2.78%$70M+$23M0.70%$3.4BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Taysha Gene Therapies, Inc.Nasdaq: TSHACurrentBiological Products, (No Diagnostic Substances)COM SHS13,560,25800.0%4.16%$66M-$26M0.67%$1.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Orchestra BioMed Holdings, Inc.Nasdaq: OBIOCurrentSurgical & Medical Instruments & ApparatusCOM9,556,06300.0%12.14%$59M+$18M0.60%$551MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Verastem, Inc.Nasdaq: VSTMCurrentPharmaceutical PreparationsCOM NEW6,718,081+82,288+1.2%5.33%$54M+$29M0.55%$864MQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
DanaherNYSE: DHRCurrentIndustrial Instruments For Measurement, Display, and ControlCOM230,00000.0%0.03%$51M+$7M0.51%$155BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Hinge Health, Inc.NYSE: HNGECurrentServices-Computer Processing & Data PreparationCL A500,00000.0%$49M+$7M0.49%$8.8BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
ROCKET PHARMACEUTICALS, INC.Nasdaq: RCKTCurrentPharmaceutical PreparationsCOM17,687,772-350,000-1.9%15.84%$47M-$14M0.47%$236MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Solid Biosciences Inc.Nasdaq: SLDBCurrentBiological Products, (No Diagnostic Substances)COM NEW5,905,426+2,012,500+51.7%5.29%$43M+$4M0.43%$719MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Neurogene Inc.Nasdaq: NGNECurrentPharmaceutical PreparationsCOM1,512,456+150,000+11.0%7.31%$42M-$0.8M0.42%$475MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Cullinan Therapeutics, Inc.Nasdaq: CGEMCurrentBiological Products, (No Diagnostic Substances)COM2,364,34700.0%3.64%$36M-$7M0.37%$589MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Aquestive Therapeutics, Inc.Nasdaq: AQSTCurrentPharmaceutical PreparationsCOM7,426,47100.0%5.91%$34M+$3M0.35%$466MQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Candel Therapeutics, Inc.Nasdaq: CADLCurrentBiological Products, (No Diagnostic Substances)COM3,211,008-3,211,010-50.0%4.09%$34M-$33M0.34%Q3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Aktis Oncology, Inc.Nasdaq: AKTSCurrentPharmaceutical PreparationsCOM1,592,04300.0%$31M-$20M0.31%$915MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Savara IncNasdaq: SVRACurrentPharmaceutical PreparationsCOM5,952,38000.0%2.70%$31M-$6M0.31%$1.1BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Korsana Biosciences, Inc.Nasdaq: KRSACurrentPharmaceutical PreparationsCOM877,020+877,020New1.93%$28M+$28M0.28%Q3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Kymera Therapeutics, Inc.Nasdaq: KYMRCurrentBiological Products, (No Diagnostic Substances)COM240,00000.0%0.28%$27M-$0.7M0.27%$10.2BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Dianthus Therapeutics, Inc. /DE/Nasdaq: DNTHCurrentPharmaceutical PreparationsCOM248,06300.0%0.44%$22M-$2M0.22%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Beta Bionics, Inc.Nasdaq: BBNXCurrentSurgical & Medical Instruments & ApparatusCOM998,855-501,145-33.4%1.84%$19M-$5M0.19%$724MQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Larimar Therapeutics, Inc.Nasdaq: LRMRCurrentPharmaceutical PreparationsCOM5,820,891+3,254,892+126.8%5.56%$19M+$11M0.19%$337MQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Pyxis Oncology, Inc.Nasdaq: PYXSCurrentPharmaceutical PreparationsCOMMON STOCK6,506,229+6,506,229New5.44%$15M+$15M0.15%$201MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Century Therapeutics, Inc.Nasdaq: IPSCCurrentBiological Products, (No Diagnostic Substances)COM8,695,65200.0%4.79%$15M-$6M0.15%$240MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Beam Therapeutics Inc.Nasdaq: BEAMCurrentBiological Products, (No Diagnostic Substances)COM570,39400.0%0.55%$14M-$6M0.14%$2.2BQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Surrozen, Inc./DENasdaq: SRZNCurrentBiological Products, (No Diagnostic Substances)COM NEW393,560+393,560New2.06%$13M+$13M0.13%Q3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Heartflow, Inc.Nasdaq: HTFLCurrentSurgical & Medical Instruments & ApparatusCOM250,000-45,000-15.3%0.28%$12M+$4M0.13%$3.9BQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Freenome, Inc.Nasdaq: FRNMCurrentServices-Medical LaboratoriesCOMMON STOCK742,500+742,500New0.67%$12M+$12M0.12%Q3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Latigo Biotherapeutics, Inc.Nasdaq: LTGOCurrentPharmaceutical PreparationsCOM700,000+700,000New1.06%$12M+$12M0.12%$878MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Silence Therapeutics plcNasdaq: SLNCurrentPharmaceutical PreparationsADS700,000+700,000New0.38%$8M+$8M0.08%$1.2BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Ocugen, Inc.Nasdaq: OCGNCurrentBiological Products, (No Diagnostic Substances)COM6,666,66600.0%1.96%$7M-$3M0.07%$249MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Milestone Pharmaceuticals Inc.Nasdaq: MISTCurrentPharmaceutical PreparationsCOM7,833,33600.0%6.29%$7M-$4M0.07%$50MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
ADARx Pharmaceuticals, Inc.Nasdaq: ADRXCurrentPharmaceutical PreparationsCOM300,000+300,000New0.27%$6M+$6M0.06%$1.6BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
CRESCENT BIOPHARMA, INC.Nasdaq: CBIOCurrentPharmaceutical PreparationsCOM372,85600.0%0.96%$5M-$1M0.05%$539MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Allogene Therapeutics, Inc.Nasdaq: ALLOCurrentBiological Products, (No Diagnostic Substances)COM3,250,00000.0%0.94%$5M-$2M0.05%$231MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Lumexa Imaging Holdings, Inc.Nasdaq: LMRICurrentServices-Medical LaboratoriesCOM500,000-150,000-23.1%0.52%$5M-$2M0.05%$1.4BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Dyne Therapeutics, Inc.Nasdaq: DYNCurrentPharmaceutical PreparationsCOM300,000+300,000New0.16%$5M+$5M0.05%$3.0BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
REGENXBIO Inc.Nasdaq: RGNXCurrentBiological Products, (No Diagnostic Substances)COM555,555+555,555New0.84%$4M+$4M0.04%$475MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Kalaris Therapeutics, Inc.Nasdaq: KLRSCurrentBiological Products, (No Diagnostic Substances)COM1,300,00000.0%5.46%$4M-$2M0.04%Q3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Abivax S.A.Nasdaq: ABVXCurrentPharmaceutical PreparationsSPONSORED ADS26,40000.0%$3M-$0.9M0.03%$7.1BQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Medline Inc.Nasdaq: MDLNCurrentSurgical & Medical Instruments & ApparatusCOM CL A70,00000.0%$2M-$0.3M0.02%$49.8BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
CAPRICOR THERAPEUTICS, INC.Nasdaq: CAPRCurrentPharmaceutical PreparationsCOM NEW250,00000.0%0.43%$2M-$4M0.02%$438MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Disc Medicine, Inc.Nasdaq: IRONCurrentPharmaceutical PreparationsCOM30,00000.0%0.07%$2M-$0.2M0.02%$3.5BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Evommune, Inc.NYSE: EVMNCurrentPharmaceutical PreparationsCOM SHS208,071-1,294,164-86.1%0.50%$2M-$18M0.02%$299MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Obsidian Therapeutics, Inc.Nasdaq: OBXCurrentPharmaceutical PreparationsCOM67,706+67,706New0.11%$0.9M+$0.9M0.01%$751MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Lexeo Therapeutics, Inc.Nasdaq: LXEOCurrentBiological Products, (No Diagnostic Substances)COM239,149+239,149New0.29%$0.8M+$0.8M0.01%$244MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Avidity Biosciences IncExitedCOM0-11,372,829-100.0%-$496MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Verona Pharma PLCExitedSPONSORED ADS0-3,051,878-100.0%-$289MQ3 202514 Nov 2025Q4 2024Q2 202513F, Q2 2025
Penumbra IncNYSE: PENExitedSurgical & Medical Instruments & ApparatusCOM0-866,499-100.0%-$269M$12.6BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Akero Therapeutics IncExitedCOM0-5,477,561-100.0%-$260MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Apogee Therapeutics IncExitedCOM0-2,782,097-100.0%-$234MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
GERON CORPNasdaq: GERNExitedPharmaceutical PreparationsCOM0-44,111,916-100.0%-$200M$588MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Merus N VExitedCOM0-2,025,277-100.0%-$191MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Axsome Therapeutics, Inc.Nasdaq: AXSMExitedPharmaceutical PreparationsCOM0-888,001-100.0%-$162M$7.1BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Apellis Pharmaceuticals IncExitedCOM0-3,685,045-100.0%-$148MQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
Bruker CorpExitedCOM0-2,481,119-100.0%-$145MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Intuitive SurgicalNasdaq: ISRGExitedOrthopedic, Prosthetic & Surgical Appliances & SuppliesCOM NEW0-220,000-100.0%-$101M$138BQ2 202614 Aug 2026Q1 2025Q1 202613F, Q1 2026
INSULET CORPNasdaq: PODDExitedSurgical & Medical Instruments & ApparatusCOM0-324,600-100.0%-$92M$9.5BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Masimo CorpExitedCOM0-683,294-100.0%-$89MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Alkermes plc.Nasdaq: ALKSExitedPharmaceutical PreparationsSHS0-1,672,356-100.0%-$88M$7.8BQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
GLOBUS MEDICAL INCNYSE: GMEDExitedSurgical & Medical Instruments & ApparatusCL A0-1,125,000-100.0%-$82M$9.1BQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
Centessa Pharmaceuticals PLCExitedSPONSORED ADS0-2,054,175-100.0%-$82MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
ABBOTT LABORATORIESNYSE: ABTExitedPharmaceutical PreparationsCOM0-444,000-100.0%-$60M$180BQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
RAPT TherapeuticsExitedCOM NEW0-1,637,165-100.0%-$55MQ1 202615 May 2026Q4 2024Q4 202513F, Q4 2025
Crinetics Pharmaceuticals IncExitedCOM0-1,451,326-100.0%-$53MQ2 202614 Aug 2026Q2 2025Q1 202613F, Q1 2026
QUEST DIAGNOSTICS INCNYSE: DGXExitedServices-Medical LaboratoriesCOM0-250,000-100.0%-$48M$28.5BQ4 202517 Feb 2026Q1 2025Q3 202513F, Q3 2025
LENZ Therapeutics, Inc.Nasdaq: LENZExitedBiological Products, (No Diagnostic Substances)COM0-863,389-100.0%-$40M$105MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Waystar Holding Corp.Nasdaq: WAYExitedServices-Computer Integrated Systems DesignCOM0-1,630,000-100.0%-$39M$5.2BQ2 202614 Aug 2026Q1 2026Q1 202613F, Q1 2026
ARROWHEAD PHARMACEUTICALS, INC.Nasdaq: ARWRExitedPharmaceutical PreparationsCOM0-585,682-100.0%-$37M$6.2BQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
Soleno Therapeutics IncExitedCOM0-424,408-100.0%-$36MQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
MoonLake ImmunotherapeuticsNasdaq: MLTXExitedPharmaceutical PreparationsCLASS A ORD0-741,090-100.0%-$35M$939MQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
StrykerNYSE: SYKExitedSurgical & Medical Instruments & ApparatusCOM0-100,000-100.0%-$33M$118BQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
GE HealthCare Technologies Inc.Nasdaq: GEHCExitedX-Ray Apparatus & Tubes & Related Irradiation ApparatusCOMMON STOCK0-393,500-100.0%-$30M$37.0BQ4 202517 Feb 2026Q1 2025Q3 202513F, Q3 2025
ARVINAS, INC.Nasdaq: ARVNExitedPharmaceutical PreparationsCOM0-3,334,308-100.0%-$23M$441MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Compass Therapeutics, Inc.Nasdaq: CMPXExitedBiological Products, (No Diagnostic Substances)COM0-4,186,599-100.0%-$22M$122MQ2 202614 Aug 2026Q3 2025Q1 202613F, Q1 2026
Alector, Inc.Nasdaq: ALECExitedBiological Products, (No Diagnostic Substances)COM0-6,990,806-100.0%-$21M$342MQ4 202517 Feb 2026Q3 2025Q3 202513F, Q3 2025
Fulgent Genetics, Inc.Nasdaq: FLGTExitedServices-Medical LaboratoriesCOM0-1,289,000-100.0%-$20M$692MQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
89bio IncExitedCOM0-1,967,527-100.0%-$19MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Definium Therapeutics, Inc.Nasdaq: DFTXExitedMedicinal Chemicals & Botanical ProductsCOM SHS0-400,000-100.0%-$19M$4.0BQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
GLAUKOS CorpNYSE: GKOSExitedSurgical & Medical Instruments & ApparatusCOM0-190,000-100.0%-$19M$14.1BQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Roivant Sciences Ltd.Nasdaq: ROIVExitedPharmaceutical PreparationsSHS0-1,454,273-100.0%-$17M$28.2BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Sage Therapeutics IncExitedCOM0-3,002,370-100.0%-$16MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Tourmaline Bio IncExitedCOM0-736,681-100.0%-$15MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
IDEAYA Biosciences, Inc.Nasdaq: IDYAExitedPharmaceutical PreparationsCOM0-370,370-100.0%-$14M$2.5BQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Tempus AI, Inc.Nasdaq: TEMExitedServices-Computer Programming, Data Processing, Etc.CL A0-200,000-100.0%-$12M$10.9BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
10x Genomics, Inc.Nasdaq: TXGExitedLaboratory Analytical InstrumentsCL A COM0-502,856-100.0%-$11M$7.5BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
CytomX Therapeutics, Inc.Nasdaq: CTMXExitedPharmaceutical PreparationsCOM0-3,461,500-100.0%-$11M$447MQ4 202517 Feb 2026Q2 2025Q3 202513F, Q3 2025
Ataibeckley IncExitedCOM SHS0-2,000,000-100.0%-$11MQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
IQVIA HOLDINGS INC.NYSE: IQVExitedServices-Commercial Physical & Biological ResearchCOM0-46,000-100.0%-$10M$41.3BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
TENAX THERAPEUTICS, INC.Nasdaq: TENXExitedPharmaceutical PreparationsCOM NEW0-696,570-100.0%-$10MQ3 202616 Nov 2026Q1 2025Q2 202613F, Q2 2026
Atai Beckley NVExitedSHS0-2,000,000-100.0%-$8MQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Perceptive Cap Solutions CorExitedCL A ORD SHS0-742,500-100.0%-$8MQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Jade Biosciences, Inc.Nasdaq: JBIOExitedPharmaceutical PreparationsCOM NEW0-573,205-100.0%-$8M$1.0BQ2 202614 Aug 2026Q2 2025Q1 202613F, Q1 2026
Wave Life Sciences, Inc.Nasdaq: WVEExitedPharmaceutical PreparationsSHS0-1,350,000-100.0%-$8M$536MQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Allurion Technologies IncALURWExitedCOMMON STOCK0-5,891,430-100.0%-$7MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Inventiva S.A.Nasdaq: IVAExitedPharmaceutical PreparationsADS0-1,298,702-100.0%-$7M$825MQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
PepGen Inc.Nasdaq: PEPGExitedPharmaceutical PreparationsCOM0-1,500,000-100.0%-$7M$370MQ4 202517 Feb 2026Q4 2024Q3 202513F, Q3 2025
4D Molecular Therapeutics, Inc.Nasdaq: FDMTExitedBiological Products, (No Diagnostic Substances)COM0-475,737-100.0%-$6M$604MQ3 202616 Nov 2026Q4 2025Q2 202613F, Q2 2026
Maze Therapeutics, Inc.Nasdaq: MAZEExitedBiological Products, (No Diagnostic Substances)COM0-212,000-100.0%-$6M$1.8BQ3 202616 Nov 2026Q2 2026Q2 202613F, Q2 2026
Cargo Therapeutics IncExitedCOM0-1,212,562-100.0%-$5MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Mind Medicine Mindmed IncExitedCOM NEW0-300,000-100.0%-$4MQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Corvus Pharmaceuticals, Inc.Nasdaq: CRVSExitedPharmaceutical PreparationsCOM0-447,607-100.0%-$3M$844MQ1 202615 May 2026Q4 2024Q4 202513F, Q4 2025
Kestra Medical Technologies Ltd.ExitedSHS0-200,000-100.0%-$3MQ3 202514 Nov 2025Q1 2025Q2 202513F, Q2 2025
Avalo Therapeutics, Inc.Nasdaq: AVTXExitedPharmaceutical PreparationsCOM NEW0-175,000-100.0%-$3M$390MQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
Acelyrin IncExitedCOM0-978,310-100.0%-$3MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
BioAge Labs, Inc.Nasdaq: BIOAExitedPharmaceutical PreparationsCOM0-786,353-100.0%-$3M$216MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Ceribell, Inc.Nasdaq: CBLLExitedElectromedical & Electrotherapeutic ApparatusCOM0-150,000-100.0%-$3M$1.0BQ3 202514 Nov 2025Q4 2024Q2 202513F, Q2 2025
Omada Health, Inc.Nasdaq: OMDAExitedServices-Health ServicesCOM0-200,000-100.0%-$3M$775MQ2 202614 Aug 2026Q2 2025Q1 202613F, Q1 2026
Essa Pharma IncExitedCOM NEW0-1,113,002-100.0%-$2MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
ImageneBio, Inc.Nasdaq: IMAExitedBiological Products, (No Diagnostic Substances)COM0-334,445-100.0%-$2M$50MQ3 202616 Nov 2026Q3 2025Q2 202613F, Q2 2026
SAB Biotherapeutics, Inc.Nasdaq: SABSExitedBiological Products, (No Diagnostic Substances)COM NEW0-635,276-100.0%-$2M$262MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Artiva Biotherapeutics, Inc.Nasdaq: ARTVExitedBiological Products, (No Diagnostic Substances)COM0-148,844-100.0%-$2M$189MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
EXAGEN INC.Nasdaq: XGNExitedServices-Medical LaboratoriesCOM0-195,000-100.0%-$0.9MQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Adagio Med Hldgs IncExitedCOM0-209,361-100.0%-$0.4MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
IMMUNIC, INC.Nasdaq: IMUXExitedPharmaceutical PreparationsCOM0-402,107-100.0%-$0.3M$117MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025